# EDGAR Filing Document

**Accession Number:** 0001496671
**File Stem:** 0001193125-23-070159
**Filing Date:** 2023-3
**Character Count:** 2812
**Document Hash:** 66eacac840e3f7081d90ad120ac78766
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-070159.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001193125-23-070159

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**EFFECTIVENESS DATE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calithera Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001496671
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 272366329
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36644
- **FILM NUMBER:** 23731181

**BUSINESS ADDRESS:**
- **STREET 1:** 343 OYSTER POINT BLVD #200
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-870-1000

**MAIL ADDRESS:**
- **STREET 1:** 343 OYSTER POINT BLVD #200
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 15** 

------

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR** 

**SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF** 

**THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-36644**

------

## Calithera Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

------

**343 Oyster Point Blvd., Suite 200** 

**South San Francisco, California 94080** 

**(650) 870-1000** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, $0.0001 par value** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 13.

Pursuant to the requirements of the Securities Exchange Act of 1934, Calithera Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: March 14, 2023 | By: | /S/ SUSAN M. MOLINEAUX, PH.D. |
|  | Name: | Susan M. Molineaux, Ph.D. |
|  | Title: | President and Chief Executive Officer |

---

------